Spyre Therapeutics (SYRE) Other financing activities (2016 - 2023)

Spyre Therapeutics has reported Other financing activities for 7 years, with the latest figure at $1.8 million in Q2 2023.

• For the quarter ending Q2 2023, Other financing activities fell 12.0% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2023 stood at $6.5 million (down 22.14% YoY), and the FY2024 full-year result was $1000.0, up 106.25% from the prior year.
• Other financing activities for Q2 2023 stood at $1.8 million, up from $1.7 million in the prior quarter.
• The five-year high for Other financing activities was $2.1 million in Q3 2021, with the low at $1.1 million in Q1 2019.
• Historically, Other financing activities has averaged $1.7 million across 5 years, with a median of $1.7 million in 2020.
• Annual changes were most pronounced in 2020 — Other financing activities surged 36.15% — and 2022, when it tumbled 31.85%.
• Spyre Therapeutics' Other financing activities stood at $1.2 million in 2019, then soared by 36.15% to $1.6 million in 2020, then grew by 29.9% to $2.1 million in 2021, then plunged by 31.85% to $1.4 million in 2022, then climbed by 24.39% to $1.8 million in 2023.
• The last three Other financing activities figures came in at $1.8 million (Q2 2023), $1.7 million (Q1 2023), and $1.4 million (Q4 2022), per Business Quant data.